P1121: TAKEAIM LYMPHOMA- AN OPEN-LABEL, DOSE ESCALATION AND EXPANSION TRIAL OF EMAVUSERTIB (CA-4948) IN COMBINATION WITH IBRUTINIB IN PATIENTS WITH RELAPSED OR REFRACTORY HEMATOLOGIC MALIGNANCIES
HemaSphere | June 23, 2022 | Volume: 6 | Issue: No issue available | Pages: 1011-1012
10.1097/01.hs9.0000847352.16311.ea